James Hatton on licensing: ZymoGenetics Novo Nordisk Recombinant Factor XIII License

<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener("load", function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <iframe src="http://www.blogger.com/navbar.g?targetBlogID=6223270&blogName=James+Hatton+on+licensing&publishMode=PUBLISH_MODE_FTP&navbarType=BLUE&layoutType=CLASSIC&searchRoot=http%3A%2F%2Fblogsearch.google.com%2F&blogLocale=en_CA&homepageUrl=http%3A%2F%2Fwww.jameshatton.com%2Fpublic%2F" marginwidth="0" marginheight="0" scrolling="no" frameborder="0" height="30px" width="100%" id="navbar-iframe" allowtransparency="true" title="Blogger Navigation and Search"></iframe> <div></div>

Friday, January 20, 2006

ZymoGenetics Novo Nordisk Recombinant Factor XIII License

The Press release for "ZymoGenetics Licenses Recombinant Factor XIII to Novo Nordisk", dated October 5, 2004.

The License Agreement for Recombinant Factor XIII, dated October 4, 2004 (full text).

0 Comments:

Links to this post:

<$BlogBacklinkTitle$>: <$BlogBacklinkSnippet$>
posted by <$BlogBacklinkAuthor$> @ <$BlogBacklinkDateTime$>

Create a Link

<< Home

: Name: James Hatton; Location: Vancouver, British Columbia, Canada

I am a partner in Vancouver-based Farris, Vaughan, Wills & Murphy LLP. I focus my practice on assisting companies to exploit the value of their intellectual property assets, with a special interest in licensing and related transactions.

View my complete profile

James Hatton on licensing

Friday, January 20, 2006

ZymoGenetics Novo Nordisk Recombinant Factor XIII License

0 Comments:

Links to this post:

About Me

Previous Posts